文献速递骨显像与常规 SPECT核素与放射性配体治疗肿瘤 PET/CT

68Ga-PSMA PET/CT 用于转移性前列腺癌 223Ra 治疗的疗效评估

68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer.
PubMed 文献 · J Nucl Med · 2023-08-03

这项前瞻性多中心影像探索研究纳入 28 例适合 223Ra 治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,于基线、223Ra 治疗 3 和 6 周期后及治疗失败时行 CT、骨显像和 68Ga-PSMA PET/CT。视觉疗效评估标准在 68Ga-PSMA PET/CT 和骨显像上均无法区分良好与不良缓解者;68Ga-PSMA PET/CT 所测骨内总肿瘤体积(TTVbone)基线较低者临床结局最好,但治疗中两组 TTVbone 均升高。

要点

  • 视觉评估标准在 68Ga-PSMA PET/CT 和骨显像上均无法区分良好与不良缓解者。
  • 68Ga-PSMA PET/CT 所测基线 TTVbone 较低者临床结局最好,但治疗中两组 TTVbone 均升高。
  • 多数患者 68Ga-PSMA 所示 TTVbone 缓解存在患者内异质性。

核心结论

  • 68Ga-PSMA PET/CT 上 TTVbone 较低的 mCRPC 患者接受 223Ra 治疗后临床结局最好。
  • 多数患者缓解高度异质。
  • 多数患者出现的碱性磷酸酶(ALP)下降与 TTVbone 下降不相关,这可能使人质疑 ALP 在临床实践中用于 223Ra 治疗期间疾病监测的价值。

研究设计与样本

  • 前瞻性、多中心、影像探索研究,2019 至 2022 年间纳入 28 例适合 223Ra 治疗的 mCRPC 患者。
  • 患者按标准治疗接受 223Ra。
  • 研究流程包括基线、223Ra 治疗 3 和 6 周期后及治疗失败时行 CT、骨显像和 68Ga-PSMA PET/CT。
  • 在 68Ga-PSMA PET/CT 上测定骨内总肿瘤体积(TTVbone)。
  • 使用新开发的图像配准工具对 PET/CT 序贯图像研究患者内缓解异质性。

主要发现

  • 视觉缓解评估标准在 68Ga-PSMA PET/CT 和骨显像上均无法区分良好缓解者与不良缓解者。
  • 68Ga-PSMA PET/CT 上基线 TTVbone 在良好缓解者中低于不良缓解者,而治疗期间两组 TTVbone 均升高。
  • 223Ra 治疗期间出现新发骨外转移的患者 TTVbone 更高。
  • 基线时 TTVbone 与 ALP 相关,但治疗中 TTVbone 与 ALP 的变化不相关。
  • 多数患者 68Ga-PSMA 所示 TTVbone 缓解存在患者内异质性。

关键数值与推荐

  • 良好缓解者与不良缓解者的判定采用无失败生存,截断值为 24 周。
  • ALP 缓解于 3 周期后评估。
  • 视觉缓解评估在 CT、骨显像和 68Ga-PSMA PET/CT 三种影像模态上进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CT and bone scintigraphy are not useful for response evaluation of bone metastases to 223Ra treatment in metastatic castration-resistant prostate cancer (mCRPC). PET using 68Ga prostate-specific membrane antigen 11 (68Ga-PSMA) is a promising tool for response evaluation of mCRPC. The aim of this study was to determine the utility of 68Ga-PSMA PET/CT for response evaluation of 223Ra treatment in patients with mCRPC. Methods: Within this prospective, multicenter, imaging discovery study, 28 patients with mCRPC, eligible for 223Ra treatment, were included between 2019 and 2022. Patients received 223Ra according to the standard of care. Study procedures included CT, bone scintigraphy, and 68Ga-PSMA PET/CT at baseline, after 3 and 6 cycles of 223Ra treatment, and on treatment failure. Response to 223Ra treatment was visually assessed on all 3 imaging modalities. Total tumor volume within bone (TTVbone) was determined on 68Ga-PSMA PET/CT. Intrapatient heterogeneity in response was studied using a newly developed image-registration tool for sequential images of PET/CT. Results were compared with failure-free survival (good responders vs. poor responders; cutoff, 24 wk) and alkaline phosphatase (ALP) response after 3 cycles. Results: Visual response assessment criteria could not distinguish good responders from poor responders on 68Ga-PSMA PET/CT and bone scintigraphy. For 68Ga-PSMA PET/CT, TTVbone at baseline was lower in good responders than in poor responders, whereas TTVbone increased in both groups during treatment. TTVbone was higher in patients with new extraosseous metastases during 223Ra treatment. Although TTVbone and ALP correlated at baseline, changes in TTVbone and ALP on treatment did not. 68Ga-PSMA response of TTVbone showed intrapatient heterogeneity in most patients. Conclusion: mCRPC patients with lower TTVbone on 68Ga-PSMA PET/CT have the best clinical outcome after 223Ra treatment. Response is highly heterogeneous in most patients. A decrease in ALP, which occurred in most patients, was not correlated with a decrease in TTVbone, which might make one question the value of ALP for disease monitoring during 223Ra treatment in clinical practice.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. de Jong AC, Segbers M, Ling SW, et al. 68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer. J Nucl Med. 2023. PMID: 37536738. doi:10.2967/jnumed.123.265489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。